These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 19231487

  • 1. Evaluation of recombinant platelet-activating factor acetylhydrolase for reducing the incidence and severity of post-ERCP acute pancreatitis.
    Sherman S, Alazmi WM, Lehman GA, Geenen JE, Chuttani R, Kozarek RA, Welch WD, Souza S, Pribble J, rPAF-AH ERCP Study Group.
    Gastrointest Endosc; 2009 Mar; 69(3 Pt 1):462-72. PubMed ID: 19231487
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial.
    Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J, Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators.
    Crit Care Med; 2004 Feb; 32(2):332-41. PubMed ID: 14758145
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk.
    Sherman S, Cheng CL, Costamagna G, Binmoeller KF, Puespoek A, Aithal GP, Kozarek RA, Chen YK, Van Steenbergen W, Tenner S, Freeman M, Monroe P, Geffner M, Deviere J, Interleukin-10 ERCP Study Group.
    Pancreas; 2009 Apr; 38(3):267-74. PubMed ID: 19214137
    [Abstract] [Full Text] [Related]

  • 4. Does obesity confer an increased risk and/or more severe course of post-ERCP pancreatitis?: a retrospective, multicenter study.
    Deenadayalu VP, Blaut U, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Temkit M, Lehman GA, Sherman S.
    J Clin Gastroenterol; 2008 Apr; 42(10):1103-9. PubMed ID: 18936645
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of postprocedure administration of gabexate mesylate in the prevention of post-ERCP pancreatitis: a randomized, controlled, multicenter study.
    Manes G, Ardizzone S, Lombardi G, Uomo G, Pieramico O, Porro GB.
    Gastrointest Endosc; 2007 Jun; 65(7):982-7. PubMed ID: 17531632
    [Abstract] [Full Text] [Related]

  • 6. Twenty-four hour prophylaxis with increased dosage of octreotide reduces the incidence of post-ERCP pancreatitis.
    Thomopoulos KC, Pagoni NA, Vagenas KA, Margaritis VG, Theocharis GI, Nikolopoulou VN.
    Gastrointest Endosc; 2006 Nov; 64(5):726-31. PubMed ID: 17055865
    [Abstract] [Full Text] [Related]

  • 7. Risk factors for post-ERCP pancreatitis: a prospective multicenter study.
    Cheng CL, Sherman S, Watkins JL, Barnett J, Freeman M, Geenen J, Ryan M, Parker H, Frakes JT, Fogel EL, Silverman WB, Dua KS, Aliperti G, Yakshe P, Uzer M, Jones W, Goff J, Lazzell-Pannell L, Rashdan A, Temkit M, Lehman GA.
    Am J Gastroenterol; 2006 Jan; 101(1):139-47. PubMed ID: 16405547
    [Abstract] [Full Text] [Related]

  • 8. The prophylactic effect of somatostatin on post-therapeutic endoscopic retrograde cholangiopancreatography pancreatitis: a randomized, multicenter controlled trial.
    Lee KT, Lee DH, Yoo BM.
    Pancreas; 2008 Nov; 37(4):445-8. PubMed ID: 18953260
    [Abstract] [Full Text] [Related]

  • 9. Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study.
    De Palma GD, Catanzano C.
    Am J Gastroenterol; 1999 Apr; 94(4):982-5. PubMed ID: 10201469
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: effects on technical success and post-ERCP pancreatitis.
    Kaffes AJ, Bourke MJ, Ding S, Alrubaie A, Kwan V, Williams SJ.
    Gastrointest Endosc; 2006 Sep; 64(3):351-7. PubMed ID: 16923481
    [Abstract] [Full Text] [Related]

  • 11. Nafamostat mesylate in the prevention of post-ERCP pancreatitis and risk factors for post-ERCP pancreatitis.
    Choi CW, Kang DH, Kim GH, Eum JS, Lee SM, Song GA, Kim DU, Kim ID, Cho M.
    Gastrointest Endosc; 2009 Apr; 69(4):e11-8. PubMed ID: 19327467
    [Abstract] [Full Text] [Related]

  • 12. A prospective, randomized, placebo-controlled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis.
    Budzyńska A, Marek T, Nowak A, Kaczor R, Nowakowska-Dulawa E.
    Endoscopy; 2001 Sep; 33(9):766-72. PubMed ID: 11558030
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial.
    Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, Schmidt S, Lazzell-Pannell L, Lehman GA.
    Gastrointest Endosc; 2007 Dec; 66(6):1126-32. PubMed ID: 18061712
    [Abstract] [Full Text] [Related]

  • 14. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial.
    Katsinelos P, Fasoulas K, Paroutoglou G, Chatzimavroudis G, Beltsis A, Terzoudis S, Katsinelos T, Dimou E, Zavos C, Kaltsa A, Kountouras J.
    Endoscopy; 2012 Jan; 44(1):53-9. PubMed ID: 22198776
    [Abstract] [Full Text] [Related]

  • 15. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP.
    Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M.
    Am J Gastroenterol; 2007 May; 102(5):978-83. PubMed ID: 17355281
    [Abstract] [Full Text] [Related]

  • 16. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. Gabexate in digestive endoscopy--Italian Group.
    Cavallini G, Tittobello A, Frulloni L, Masci E, Mariana A, Di Francesco V.
    N Engl J Med; 1996 Sep 26; 335(13):919-23. PubMed ID: 8786777
    [Abstract] [Full Text] [Related]

  • 17. Can a single dose corticosteroid reduce the incidence of post-ERCP pancreatitis? A randomized, prospective control study.
    Kwanngern K, Tiyapattanaputi P, Wanitpukdeedecha M, Navicharern P.
    J Med Assoc Thai; 2005 Sep 26; 88 Suppl 4():S42-5. PubMed ID: 16623000
    [Abstract] [Full Text] [Related]

  • 18. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis.
    Sternlieb JM, Aronchick CA, Retig JN, Dabezies M, Saunders F, Goosenberg E, Infantolino A, Ionna S, Maislin G, Wright SH.
    Am J Gastroenterol; 1992 Nov 26; 87(11):1561-6. PubMed ID: 1279967
    [Abstract] [Full Text] [Related]

  • 19. Comparison of two dosing regimens of gabexate in the prophylaxis of post-ERCP pancreatitis.
    Masci E, Cavallini G, Mariani A, Frulloni L, Testoni PA, Curioni S, Tittobello A, Uomo G, Costamagna G, Zambelli S, Macarri G, Innocenti P, Dragonetti C, Gabexate in Digestive Endoscopy-Italian Group II.
    Am J Gastroenterol; 2003 Oct 26; 98(10):2182-6. PubMed ID: 14572565
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis.
    Dumot JA, Conwell DL, Zuccaro G, Vargo JJ, Shay SS, Easley KA, Ponsky JL.
    Am J Gastroenterol; 2001 Jul 26; 96(7):2098-102. PubMed ID: 11467638
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.